Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 7/20 | 0.47 |
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | CASR | P41180 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13066397 | 0.80 | MMP8 (0.55) | EPHX2HPGD | |
| SCHEMBL5357017 | 0.79 | MTNR1A (0.54) | MTNR1AMTNR1BEPHX2CNR1CNR2 | |
| SCHEMBL13066966 | 0.77 | SMN1; SMN2 (0.68) | MTNR1AMTNR1BEPHX2CNR1CNR2 | |
| SCHEMBL4219824 | 0.72 | MTNR1A (1.00) | MTNR1AMTNR1BEPHX2CNR1CNR2 | |
| SCHEMBL20825093 | 0.72 | MTNR1A (0.68) | MTNR1AMTNR1BEPHX2CNR1CNR2 | |
| SCHEMBL5363722 | 0.72 | AOC3 (0.49) | EPHX2 | |
| SCHEMBL7443581 | 0.71 | SMN1; SMN2 (0.43) | MTNR1AMTNR1BEPHX2NPSR1 | |
| SCHEMBL2726416 | 0.69 | MTNR1A (0.72) | MTNR1AMTNR1BEPHX2CNR1CNR2 | |
| SCHEMBL23729560 | 0.67 | SPHK1 (0.35) | — | |
| SCHEMBL8083629 | 0.67 | KDM1A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | MTNR1A 1999/4885MTNR1B 1866/4885EPHX2 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.